Novel Approach to Peptide Therapy for Rheumatoid Arthritis

肽治疗类风湿关节炎的新方法

• 批准号: 419073
• 负责人: Barra Lillian
• 金额: $ 66.88万
• 依托单位: University of Western Ontario
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-03-01 至 2025-03-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=419073&lang=en
• 关键词: Hla-Dr4; Human T Cell Responses; Immune Responses To Citrullinated Antigens; Immune Responses To Homocitrullinated Antigens; Joint Histopathology; Mouse Models Of Arthritis; Peptide Treatment And Delivery Methods; Pre-Clinical Imaging; Pre-Clinical Locomo

Rheumatoid Arthritis (RA) is a painful, chronic autoimmune disease that damages joints and causes disability. RA is the most common autoimmune inflammatory arthritis affecting >300,000 Canadians. There is no cure for RA and its cause is unknown. Currently

类风湿关节炎 (RA) 是一种痛苦的慢性自身免疫性疾病，会损害关节并导致残疾。 RA 是最常见的自身免疫性炎症性关节炎，影响超过 300,000 名加拿大人。 RA 无法治愈，其原因尚不清楚。现在